# REACH (Galleri in the Medicare population)

Source: https://onco.cc/trials/reach-galleri-medicare/  
OnCo record `reach-galleri-medicare` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A study of up to 50,000 older Americans on Medicare that gives them the Galleri test and compares how many cancers are found at stage IV.

## Summary

REACH (NCT05673018) is a non-randomised interventional study sponsored by GRAIL, Inc. Its registry primary outcome is the incidence of stage IV cancers; it assesses real-world clinical impact, safety and test performance.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 50,000 participants, a start on 12 July 2024 and primary completion expected in September 2030.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: REACH study; GRAIL-MA-002; Galleri-Medicare
- Registry id: NCT05673018
- Phase: not-applicable
- Setting: People in the Medicare population in the United States, given Galleri in a comparative prospective cohort with enrolment meant to represent Medicare beneficiaries
- Sponsor: GRAIL, Inc.
- Enrolled: 50000

## Sources

- ClinicalTrials.gov NCT05673018: https://clinicaltrials.gov/study/NCT05673018

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- companies: [GRAIL](https://onco.cc/companies/grail/)

---
JSON: https://onco.cc/api/v1/entities/reach-galleri-medicare.json